ADDF In The Media

Scientific American - A New Idea for Treating Alzheimer’s

09/30/2014

If it’s good for the heart, it could also be good for the neurons, astrocytes and oligodendrocytes, cells that make up the main items on the brain’s parts list. The heart-brain adage comes from epidemiological studies that show that people with cardiovascular risk factors such as high-blood pressure and elevated cholesterol levels, may be more at risk for Alzheimer’s and other dementias. This connection between heart and brain has also led to some disappointments: clinical trials of lipid-lowering statins have not helped patients diagnosed with Alzheimer’s, although epidemiological studies suggest that long-term use of the drugs may help prevent Alzheimer’s and other dementias.

Huffington Post - 5 Reasons to Be Optimistic About Alzheimer’s Research

08/08/2014

Earlier this month I joined some of the world's preeminent physicians and neuroscientists in Copenhagen, Denmark, for the Alzheimer's Association's International Conference (AAIC). The six-day gathering is the largest of its kind and featured more than 100 sessions on a diverse range of Alzheimer's topics. Those sessions represent an incredible amount of new material and research to digest, so I've narrowed down the highlights for those of you who are interested in tracking the latest in Alzheimer's research and drug development:

National Post - A First-Hand Account of Alzheimer’s ‘Long Goodbye’

07/30/2014

Joan’s book, from the viewpoint of a caregiver, is an emotionally charged eulogy by a spouse who cared for her husband at home until the end. “Alzheimer’s is a disease of the brain that is paid for with the currency of the heart,” she said. “Old age is definitely not for sissies.” She is a member of the Board of Overseers of the Alzheimer’s Drug Discovery Foundation (ADDF), which was co-founded by Leonard A. and Ronald S. Lauder of the Estée Lauder cosmetics family. All book proceeds will support the ADDF’s Canadian arm.

Huffington Post - My Father’s Battle with Alzheimer’s

06/16/2014

His memory loss became apparent first. Like many people experiencing Alzheimer's in its early stages, my father began misplacing important objects and forgetting the names of people. As the disease progressed, his conversational skills became increasingly impaired, but through all of his changes, our emotional bond remained strong. Eventually, it became impossible for my stepmother to care for him at home and he entered a nursing facility. I knew my father was following a typical Alzheimer's course. After more than 35 years of geriatric medical practice, I have watched this devastating disease unfold in similar ways for thousands of patients. But watching my father's mind deteriorate was uniquely painful.

The Plain Dealer - Researchers From Ohio State, Emory Receive Grants

06/06/2014

Researchers at Ohio State University and Emory University are the first to receive funding for their work in Alzheimer's through a collaboration between the Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation. The teams will each receive $101,000.

Bioscience Technology - Antidepressant Reduces Alzheimer’s Plaque Growth by 78 Percent

05/14/2014

A common antidepressant can dramatically halt growth of Alzheimer’s plaque. A team from Missouri and Pennsylvania report today in Science Translational Medicine this reduction occurs in both humans and mice. It gives the drug, the selective serotonin reuptake inhibitor (SSRI) citalopram, a possible future role as a prophylactic—the first in Alzheimer’s disease (AD), if bigger studies are supportive. “I think this is an important paper,” Howard Fillit said in an interview with Bioscience Technology. Fillit is [executive director and] chief scientific officer of the Alzheimer’s Drug Discovery Foundation. He offered a corollary, however, given that a small February JAMA study, while “exciting,” did find citalopram may cause cognitive problems after AD onset: “The biology of SSRIs is really interesting. But we have cured mice of Alzheimer’s 400 times. I hope this leads to a Phase 2b or 3 study, to look at whether citalopram and other SSRIs can be disease-modifying agents for AD.”

Outsourced Pharma - Alzheimer’s Drug Discovery Foundation Raises $1.1 Million for New Clinical Trial

05/06/2014

The Alzheimer’s Drug Discovery Foundation (ADDF) has announced it has raised more than $1.1 million for a clinical trial that will test the ability of existing drug rasagiline to treat Alzheimer’s. The funds were raised by an auction at the Eighth Annual Connoisseur’s Dinner. In all, the dinner raised over $3.5 million for drug research related to Alzheimer’s disease. Rasagiline, which is produced by Teva, is currently approved by the FDA to treat Parkinson’s disease. The clinical research will be led by Jeffrey Cummings, who is the director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio

New York Social Diary - Public Profile

05/05/2014

Last Thursday night I went down to Sotheby’s for a black tie dinner benefiting  the Alzheimer’s Drug Discovery Foundation. ADDF was created in 1998 by Leonard and Ronald Lauder, sons of Estee. In the past eight years they’ve established a public profile. 

Drug Discovery & Development - Alzheimer’s Drug Discovery Foundation Repurposes Rasagiline

05/02/2014

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it raised more than $1.1 million in support of a clinical trial to test an existing drug for the treatment of Alzheimer's disease. The $1.1 million was generated during the "Fund a Scientist" auction at its Eighth Annual Connoisseur's Dinner and awarded to Jeffrey Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nev. and Cleveland, Ohio. Cummings will investigate rasagiline, an FDA-approved treatment for Parkinson's disease with the potential to be the first drug to slow the course of Alzheimer's disease.

Washington Life Magazine - 10 Minutes with Erdem

04/25/2014

Moralioglu, who made his inaugural visit to Washington to show his Fall/Winter 2014 collection at the Alzheimer’s Drug Discovery Foundation’s annual Great Ladies Luncheon and Fashion Show, also managed to fit in visits to the Lincoln Memorial, the White House, the POV at the W Hotel and the National Cathedral. But WL snagged 10 minutes of his time on his last day in the city to chat about where he gets his inspiration for his designs, why he is fascinated by the “codes of femininity,” his ideal woman client and what real-life woman has had the biggest influence on him.